Rainwater Foundation Funds Nearly $4 Million Alzheimer's and Other Dementia Research

The Rainwater Charitable Foundation will once more fund drug discovery research toward finding therapies for Alzheimer's disease, frontotemporal degeneration, and other tauopathies in collaboration with the Alzheimer's Association, reports the Fort Worth Business Press . The foundation underwrites roughly $4 million Alzheimer's and other dementia research, which focuses on mitigating or eliminating the effects of abnormal tau in the brain. The Alzheimer's Association and Rainwater Charitable Foundation's Tau Consortium have completed a second year of the Tau Pipeline Enabling Program (T-PEP II), which this year awarded grants to eight additional research groups. The goal of T-PEP II is to expedite the timeline from drug discoveries in laboratories to clinical trials in people living with Alzheimer's and other dementia. The foundation has pledged more than $100 million to the program since the consortium's inception, and so far eight treatments have entered human trials as a result of the Rainwater family's funding. "The research we're co-funding through this program will expand the pipeline of possible treatments and accelerate the pace of progress toward finding effective treatments for Alzheimer's and other dementia," declared Alzheimer's Association executive Heather Snyder.